Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Mattie HartauerDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC, 27599-7569, USA.ORCID http://orcid.org/0000-0002-5082-0168
Henry HoDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC, 27599-7569, USA.ORCID http://orcid.org/0000-0003-1138-9149
Meimei WanWake Forest Institute of Regenerative Medicine, Winston-Salem, NC, USA.
William A MurphyDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC, 27599-7569, USA.ORCID http://orcid.org/0000-0002-7476-9248
Jacqueline B TileyDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC, 27599-7569, USA.ORCID http://orcid.org/0000-0002-9977-1184
John K FallonDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7569, USA.ORCID http://orcid.org/0000-0003-1848-0121
Colin E BishopWake Forest Institute of Regenerative Medicine, Winston-Salem, NC, USA.
Kim L R BrouwerDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7569 Kerr Hall, Chapel Hill, NC, 27599-7569, USA. kbrouwer@unc.edu.ORCID http://orcid.org/0000-0003-1945-4929
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
The UNC Chapel Hill Superfund Research Program (UNC-SRP)P42ES031007 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kathleen M Gray · 2020 to 2026
$22.2M
Mechanisms of Altered Hepatic Transport: Impact on Drug TherapyR35GM122576 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER · 2017 to 2026
$5.7M
Shared LC-MS/MS for Quantitative Targeted ProteomicsS10OD032350 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALLON, JOHN KEVIN · 2023 to 2023
$600k
Shared UPLC-MS/MS for Absolute Quantitative ProteomicsS10RR024595 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SMITH, PHILIP C · 2008 to 2008
There is growing demand for improved in vitro liver models to better predict in vivo pharmacology, specifically drug disposition mediated by hepatic transporters and assessment of transporter-mediated drug interaction risk. While 2D sandwich-cultured human hepatocytes (SCHH) remain valuable, they are limited to short-term use due to hepatocyte de-differentiation and absence of non-parenchymal cells. Multicellular hepatic spheroids (MHS) offer a promising alternative, but transporter concentrations, functionality, and suitability for hepatobiliary transport studies remain unclear. We evaluated an all-human MHS model, comprised of transporter-certified™ cryopreserved primary human hepatocytes (PHH), Kupffer, stellate, and endothelial cells, for long-term hepatic transporter assessment. Over a 21-day culture period, we monitored transporter concentrations (targeted proteomics), regulation (RNA-seq), localization (immunofluorescence), bile acid profiles (LC-MS/MS), and functional transport (B-CLEAR
Indexed as
HepatocytesLiverMembrane Transport ProteinsSpheroids, CellularBile Acids and SaltsCells, CulturedHumansKupffer CellsModels, BiologicalMultidrug Resistance-Associated Protein 2ProteomicsBile Acids and SaltsMembrane Transport ProteinsMultidrug Resistance-Associated Protein 2Bile acidsBiliary transportDrug dispositionIn vitro modelMRP2New approach methodologies (NAMs)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Evaluation of a human 3D multicellular hepatic spheroid model as a platform for studying hepatic transporters. · full record | Socratic